Forge Therapeutics Excites Big Guns In Antibiotic World
Emerging Company Profile: Forge Therapeutics, which licensed intellectual property from the University of California San Diego in 2015...
Fragment-based methods for drug screening
In the pharmaceutical industry, the “batting average” for taking a compound from discovery to a marketed therapy leaves a lot to be desired.
Why San Diego leaders must forge international economic partnerships
Did you know that the greatest public transportation systems in the world have a direct and important connection to San Diego? The ticketing [...]
Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference
-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]
Preclinical antibiotic pipeline gets a pick‑me‑up
The antibiotic pipeline is running dry. An analysis by the WHO of the development landscape for antibiotics aimed at the most dangerous bacterial [...]
Forge therapeutics announces participation in upcoming scientific and industry events
San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and [...]
Forge Therapeutics, Evotec launch platform to discover metalloenzyme inhibitors
Less than a year after forming a strategic alliance to develop novel antibiotics against some drug-resistant superbugs, Forge Therapeutics and Evotec have expanded [...]
-
Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas GalleryForge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas
Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas
- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships – [...]
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., [...]